Karen Dodge
Family · Denton, TXNPI 1669824470
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 265 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 16.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,747 and has fallen 86.0% since, to $244 in 2025. Among family clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 265 payments — averaging $17.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$755
- AbbVie$732
- Boehringer Ingelheim$500
- AstraZeneca$464
- Lilly USA, LLC$413
- Abbott$307
- plus $1K from 28 others
What the payments were for
- Food & beverage$4,652100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 38 | $755 |
| AbbVie | 43 | $732 |
| Boehringer Ingelheim | 26 | $500 |
| AstraZeneca(2 entities) | 29 | $464 |
| Lilly USA, LLC | 26 | $413 |
| Abbott | 16 | $307 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $166 |
| Biohaven Pharmaceuticals, Inc. | 6 | $124 |
| Merck | 7 | $123 |
| Sanofi-aventis U.S. LLC | 7 | $108 |
| Pfizer | 7 | $102 |
| Echosens North America, Inc. | 3 | $87 |
| Johnson & Johnson | 5 | $82 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $80 |
| Amgen | 5 | $71 |
| GSK | 4 | $64 |
| Astellas Pharma US Inc | 3 | $54 |
| Corium, LLC | 3 | $49 |
| Eisai Inc. | 3 | $48 |
| Bayer | 3 | $43 |
| Vyera Pharmaceuticals, LLC | 2 | $35 |
| Esperion Therapeutics, Inc. | 2 | $31 |
| Exact Sciences | 2 | $31 |
| Currax Pharmaceuticals LLC | 2 | $28 |
| Baxter Healthcare | 1 | $27 |
| Phathom Pharmaceuticals, Inc. | 1 | $17 |
| Mylan Specialty L.p. | 1 | $17 |
| Amarin Pharma, Inc. | 1 | $16 |
| Antares Pharma, Inc. | 1 | $14 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Sanofi | 1 | $13 |
| Paratek Pharmaceuticals, Inc. | 1 | $13 |
| Biogen | 1 | $13 |
| Nestle Healthcare Nutrition Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,652 in reported general payments places this provider in the 90th percentile of 15,456 family providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Midodrine Hcl | 14 | $372 |
| Pantoprazole Sodium | 17 | $260 |
| Flecainide Acetate | 13 | $205 |
| Montelukast Sodium | 18 | $192 |
| Levothyroxine Sodium | 15 | $177 |
| Amlodipine Besylate | 16 | $97 |
| Atorvastatin Calcium | 14 | $77 |
| Furosemide | 15 | $75 |
| Losartan Potassium | 11 | $50 |
| Lisinopril | 16 | $40 |
Paid to pharmacies, not to this prescriber.
Other family in Denton
- David WeirDallas$959K
- Robin BeachHouston$428K
- April LopezMcAllen$417K
- Sarah AguilarHouston$199K
- Sie ThomasDallas$197K
- Anna CastroSan Antonio$184K
- Jill CampbellShenandoah$182K
- Angela AchaPflugerville$174K
- Susan BowlinIrving$164K
- Stephanie RodriguezCorpus Christi$159K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.